← Russell 3000 cross-section

TCMD TACTILE SYSTEMS TECHNOLOGY INC

Trailing twelve months to 2026-06-30 · as filed 2026-08-10, not restated
Healthcare

Scale

Market cap
$538m
Revenue TTM
$350m
Net income TTM
$25m
Free cash flow
$27m
Composite score
75.9
Sector rank
#2369

Valuation

P / E
21.6
EV / EBITDA
11.2
EV / sales
1.3
FCF yield
4.99%
Earnings yield vs 10-yr
-0.10pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
7.1%
EBITDA margin
11.9%
ROE
11.1%
ROIC
22.8%
Revenue growth
17.2%

Insider activity, last 90 days

Net open-market
$-0.32m
Buyers
0
Sellers
1

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Sales and rentals of our lymphedema products represented 84% and 83% of our revenue in the six months ended June 30, 2026 and 2025, respectively. For the six months ended June 30, 2026 and 2025, sales of AffloVest represented 16% and 17% of our revenue, respectively. To support the growth of our business, we continue to invest in our commercial infrastructure, consisting of a lymphedema and respiratory sales force, marketing team including clinical education programs, patient education team, reimbursement capabilities and clinical expertise. …TACTILE SYSTEMS TECHNOLOGY INC, 10-Q, period ended 2026-06-30, filed 2026-08-10

Read the full passage →